<div class="card-body whoweAreCardBody">
    <div class="row">
        <div class="col-9">
           <div id="apf" style=" text-align:left;">
                <img id="apf1" src="assets/images/NewsLinks.jpg" />
            </div>
        <br />



        <span class="cardContent">
            <span class="cardContent">

          <h2>News</h2>
                
          <ul class="web_links">
              
            <li>  New <a href="gui-doc-faq.aspx">FAQs</a> have been uploaded to the FCIS Web Portal.</li>
              <li>FCIS conducted 4 module virtual training on cGMP on August-September:
                  <ul>
                      <li><a href="Documents/cGMP_APF_Design_part_1.pdf" target="_blank">Design for Aseptic Processing Facilities (APF) Part 1</a></li>
                      <li><a href="Documents/cGMP_APF_Design_part_2.pdf" target="_blank">Design of Aseptic Processing Facilities (APF) Part 2</a></li>
                      <li><a href="Documents/NIH_Training_CQV_Module 2020_09_08_JB.pdf" target="_blank">Commissioning, Qualification and Validation (CQV) of Aseptic Processing Facilities (APF)</a></li>
                      <li><a href="Documents/Project_Management_for_APFs_slides.pdf" target="_blank">Project Management Process for Aseptic Processing Facilities (APF) Training Module 4</a></li>
                  </ul>
              </li>     
              <li>I-IVAU Expansion was recently completed, turned over and in operation.</li>
              <li>Trailer 10A was recently completed, turned over and in operation.</li>
              <li>NCI TIL Modular construction is complete and is currently under CQV activities.</li>
              <li>CCE East Terrace Modular is nearing construction completion.</li>
              <li>DLM Sterility is nearing construction completion.</li>
              <li>12E cGMP construction has started.</li>
              <li>P-IVAU design is nearing completion.</li>
              <li>A major DRM Chapter 13 update is in development, with expected release January 2021.</li>
              <li>FCIS recently launched the DTR-FCIS FMC Application to support the monitoring and reporting process of critical environmental parameters for operational APFs. Click <a href="https://dtrdata.orf.od.nih.gov/apfdaily/" target="_blank">here</a> to access the FCM APF Daily Reports. </li>
              <li>FCIS currently deployed a major update for the DTR APF Dashboard. Click <a href="https://dtrdata.orf.od.nih.gov/cgmp/" target="_blank">here</a> to access the DTR APF Dashboard. The updates include:
                  <ul>
                      <li>Improved interface: Ability to drill down on each critical parameter, display data graphs from key plans, user-based time selector for graphing trends.</li>
                      <li>Added the newly built I-IVAU expansion into the IVAU portfolio. </li>
                  </ul>
              </li>
              </ul>
            <h2>Links</h2>
          <ul class="web_links">
            <li><a href="https://www.law.cornell.edu/uscode/text/21/353a#" target="_blank">21 U.S. Code &sect; 353a -  Pharmacy compounding</a></li>
            <li><a href="https://www.law.cornell.edu/uscode/text/21/353b#" target="_blank">21 U.S. Code § 353b - Outsourcing facilities</a></li>
            <li><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211" target="_blank">CFR - Code of Federal Regulations Title 21</a></li>
            <li><a href="https://www.orf.od.nih.gov/TechnicalResources/Pages/DRM_News_to_Use.aspx" target="_blank">DTR News to Use</a></li>
            <li><a href="https://www.orf.od.nih.gov/TechnicalResources/Pages/DTR_Technical_Bulletin.aspx" target="_blank">DTR Technical Bulletins</a></li>
            <li><a href="https://spapps.od.nih.gov/sites/dtrpermitreview/SitePages/Home.aspx" target="_blank">DTR Permit Review</a></li>
            <li><a href="https://www.fda.gov/vaccines-blood-biologics/blood-blood-products" target="_blank">FDA: Blood & Blood Products</a></li>
            <li><a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products" target="_blank">FDA: Cellular & Gene Therapy Products</a></li>
            <li><a href="https://www.fda.gov/drugs" target="_blank">FDA: Drugs</a></li>
            <li>
              <a href="https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics" target="_blank">FDA: Guidance, Compliance & Regulatory Information (Biologics)</a>

            </li>
              <li><a href="https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products" target="_blank">FDA: Tissue & Tissue Products</a></li>

               <li><a href="https://www.fda.gov/media/70975/download" target="_blank">Guidance for Industry: CGMP for Phase 1 Investigational Drugs </a></li>
            <li><a href="https://www.fda.gov/media/72253/download" target="_blank">Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants</a></li>
            <li><a href="https://www.fda.gov/media/71026/download" target="_blank">Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice</a></li>
            <li><a href="https://www.usp.org/compounding/" target="_blank">USP Compounding Standards</a></li>
            <li><a href="http://www.ashe.org/management_monographs/pdfs/mg-2019-055955-usp-797-second-edition.pdf" target="_blank">USP <797> Monograph by ASHE</a></li>
              <li><a href="https://www.ashrm.org/system/files/media/file/2019/07/USP-800_MONOGRAPH_FINAL_DIGITAL.pdf" target="_blank">USP <800> Monograph by ASHE</a></li>
            <li><a href="https://www.usp.org/compounding/795-download/thank-you" target="_blank">USP General Chapter <795>- Pharmaceutical Compounding - Non-Sterile Compounding</a></li>
            <li><a href="https://www.usp.org/compounding/797-download/thank-you" target="_blank">USP General Chapter <797>- Pharmaceutical Compounding - Sterile Preparations</a></li>

        


            <li><a href="https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare" target="_blank">USP General Chapter <800>- Hazardous Drugs - Handling in Healthcare Settings Handling Hazardous Drugs</a></li>
            <li><a href="https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/key-issues/usp35-nf30_general_chapter_823.pdf" target="_blank">USP General Chapter <823>- PET Drugs for Compounding, Investigational & Research uses</a></li>
            <li><a href="https://go.usp.org/e/323321/-medicines-general-chapter-825/3c6hn9/255392468?h=H6hOMWBTWNzIXeswDbjDiC6IfseL6Ki8xqMnSOmDo5c" target="_blank">USP General Chapter <825>- Radiopharmaceuticals – Preparation, Compounding, Dispensing, and Repackaging</a></li>

        
            
            
            
          
            
           
          </ul>

        </span>


        <div class="row">



        </div>

      </div>
    </div>
  </div>